A Phase 4 interventional study of tranexamic acid and normal saline in Postpartum Hemorrhage and Systemic Autoimmune Diseases, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by RenJi Hospital · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing Tranexamic Acid in Postpartum Hemorrhage — 8 open to participants now, 8 under way, 3 of them phase 3. Tranexamic Acid · Postpartum Hemorrhage.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, this one is the 20th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 4, and was the 46th registered.
471 studies on the registry are indexed under Postpartum Hemorrhage; 76 are open to participants now.
Browse Postpartum Hemorrhage studies →8 of the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage are open now, in 8 countries. Recruiting first, the newest first:
Wolfson Medical Center · Sites in Israel
Ages 18–51 · Women only · Healthy volunteers
Aligarh Muslim University · Sites in India
Ages 18–45 · Women only
London School of Hygiene and Tropical Medicine · Sites in Tanzania
Ages 18+ · Women only
Inova Health Care Services · Sites in United States
Ages 18–50 · Women only · Healthy volunteers
University Hospital, Bordeaux · Sites in France
Ages 18–65 · Women only
By country, each count listing its studies:
Tranexamic Acid: first FDA approval 1986 (CYKLOKAPRON). What it is approved for, and how studies give it, is on its page →
Of the 41 Postpartum Hemorrhage studies recruiting now, 21 (51%) set no upper age limit and 20 (49%) stop at 75 or younger; 6 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 50 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 18 · Phase 4 11
First in 2009; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 276 is above the median of 148 across 362 interventional studies indexed under Postpartum Hemorrhage.
Median enrollment 198 across the 50 interventional studies. Of the 35 that completed or were terminated, 7 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 50 has an industry lead sponsor. The 10 most frequent:
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
RenJi Hospital has 2 studies filed under Postpartum Hemorrhage — fewer than ten, so there is no comparison to draw.
4 of the studies testing Tranexamic Acid in Postpartum Hemorrhage that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04304625Phase 3University Hospital, BordeauxTRAnexamic Acid for Preventing Blood Loss Following a Cesarean Delivery in Women With Placenta pREVIA | 2027-06 |
| NCT05562609Phase 3London School of Hygiene and Tropical MedicineTranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher Risk | 2027-09 |
| NCT06754371RenJi HospitalProphylactic Tranexamic Acid Reduces Postpartum Hemorrhage | 2027-01 |
| NCT05370820Inova Health Care ServicesPrevention of Postpartum Hemorrhage With Tranexamic Acid | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing Tranexamic Acid in Postpartum Hemorrhage, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Postpartum hemorrhage (PPH) is the most significant leading cause of pregnancy-related mortality in high-risk cesarean delivery women. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including PPH, preeclampsia, thromboembolism, abortion, and intrauterine growth restriction. The incidence of PPH in women with systemic lupus erythematosus has been reported to be as high as 34%. Prevention of PPH is the key to reduce complications in high-risk women. In recent years, a large number of clinical studies have confirmed that the early preventive use of tranexamic acid(TXA) can reduce the amount of blood loss, the need for additional uterine contraction agents, the risk of blood transfusion, and maternal adverse outcomes, and do not increase the risk of thromboembolic events, which can be used to prevent PPH. However, the study population of TXA is mainly low-risk puerpera, and there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. The purpose of this study was to evaluate the safety and efficacy of TXA in preventing postpartum hemorrhage after cesarean delivery in women with systemic autoimmune disease, as well as the maternal and neonatal risks associated with systemic autoimmune disease, to provide evidence for clinical practice and further research.
The worldwide estimated cumulative prevalence of autoimmune disease is approximately 5%. Studies are often limited by small sample sizes and focused on a specific autoimmune disease such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), which is characterized by the production of autoantibodies leading to inflammation of multiple organs. Systemic autoimmune diseases are associated with adverse pregnancy outcomes (APOs), including increased cesarean delivery rates, PPH, preeclampsia, thromboembolism, abortion, premature delivery, and intrauterine growth restriction. Preeclampsia is the most commonly reported complication in patients with SLE and is also a high risk factor for PPH. The incidence of PPH in women with SLE has been reported to be as high as 34%. PPH increases the need for blood transfusion and related complications and is a significant clinical and socio-economic problem. Therefore, prevention of PPH is the key to reduce the postpartum complications of high-risk women. At present, the methods commonly used to prevent PPH after cesarean delivery include uterine massage, prophylactic use of uterine contraction agents in the third stage of labor, and early use of TXA. Recent clinical studies of TXA use in high-risk cesarean delivery women have shown that prophylactic use of TXA significantly reduces blood loss, prevents PPH, and reduces ICU admission and length of stay. There was no evidence of an increased risk of maternal-related complications with TXA use. But there is still a lack of relevant research on TXA used in pregnant women with systemic autoimmune diseases. Anti-phospholipid antibodies (aPL) are often present in SLE and APS patients, which predict serious perinatal complications and are associated with the risk of thrombosis. aPL are detected not only in SLE and APS but also in other connective tissue diseases such as systemic sclerosis (SSc), Sjögren's syndrome (SS), rheumatoid arthritis (RA), and undifferentiated connective tissue disease (UCTD). Although TXA has been widely used in patients at high risk for thromboembolism, such as trauma, orthopedics, and cardiac surgery in recent years, the evidence strongly supports that it does not increase the risk of death or thromboembolic complications. More evidence from high quality randomized controlled trials is needed to assess the benefits and risks of its use in women at high risk of PPH after cesarean delivery.
The aim of this study was to evaluate the safety and efficacy of TXA in preventing PPH after cesarean delivery in women with systemic autoimmune disease. Patients undergoing cesarean delivery were randomly assigned to TXA group(intravenous infusion of TXA 1g (20ml) 10min before skin dissection) and placebo group(intravenous infusion of normal saline 20ml 10min before skin dissection).The estimated blood loss 24h postoperatively, blood transfusion 3d postpartum, additional uterotonics, other surgical intervention for PPH and thromboembolic events were recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection
Drug: tranexamic acid
intravenous infusion of normal saline 20ml 10min before skin dissection
Drug: normal saline
intravenous infusion of tranexamic acid 1g (20ml) 10min before skin dissection
Also known as: TXA
intravenous infusion of normal saline 20ml 10min before skin dissection
The incidence of postpartum hemorrhage
Postpartum hemorrhage is defined as blood loss of 1000 mL or more within the first 24 h after cesarean delivery.
Time frame: From skin incision to 1day after surgery
Estimated blood loss within 1day after surgery
Estimated blood loss is calculated by GROSS EQUATION: Estimated Blood Loss (EBL) = EBV ×((HCT1 - HCT2)/(HCT mean)), EBV = Estimated Blood volume; whereas EBV = Patient's weight (in kilogram) × 70 mL/kg, HCT1=preoperative hematocrit, HCT2 = postoperative hematocrit, and HCT mean = (HCT1 + HCT2)/2;
Time frame: From skin incision to 1day after surgery
The volume of blood transfusion within 3days after surgery and complications
The volume of blood transfusion within 3days after surgery and complications(such as fever, allergy, hemolysis, renal dysfunction,etc)
Time frame: From skin incision to 3days after surgery
Whether additional uterotonics are needed
Uterotonics other than intraoperative routine dose intravenous and intrauterine infusion of oxytocin.
Time frame: From the delivery of placenta until 3 days postoperatively
Whether other surgical intervention for PPH are needed
Patients who need other surgical intervention(such as intrauterine balloon compression hemostasis, uterine artery ligation or embolization and hysterectomy) to control PPH
Time frame: From the delivery of placenta until 3 days postoperatively
Incidence of thromboembolic events
The occurrence of thromboembolic events within one week of delivery, including deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke
Time frame: Patients will be followed up to one week after surgery
Maternal complications
Occurrence of adverse effects (nausea, vomiting, headache, epilepsy, renal impairment,coagulopathy) within 3days after surgery.
Time frame: Patients will be followed up to 3days after surgery
Maternal and neonatal 3 months mortality
All-cause 3 months mortality
Time frame: Patients and neonates will be followed up to 3 months after surgery
Estimated intraoperative blood loss
Estimated intraoperative blood loss is calculated using the formula: collected blood volume in the suction canister (ml)-the volume of amniotic fluid (ml)-the volume of flushing (ml) + the volume from the gauze tampon (ml)
Time frame: From skin incision to the end of the surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jan 2027, 24 months after the start.
Of 28 non-industry phase 4 interventional studies under Postpartum Hemorrhage, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's planned 24 months is above that.
Counting every sponsor, half of 29 studies reached it within 12 months; a quarter within 10 and three quarters within 20.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tranexamic Acid